Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Innovation May Mean Collaborations for Drug Development in Future

Published: Wednesday, September 26, 2012
Last Updated: Wednesday, September 26, 2012
Bookmark and Share
Research collaborations and shared data will mark a change in the fiercely competitive pharmaceutical world, states a new report by healthcare experts GBI Research.

The new report states that academics, industry giants, regulators and patients’ organizations must work together in collaborative research projects in order for modern medicine to flourish.

Over the past decade, the number of New Drug Applications (NDAs) and Biologics License Applications (BLAs) approved by the US Food and Drug Administration (FDA) has fallen steadily, despite ever-increasing R&D expenditure. This gap between investment and success has led the pharmaceutical industry to rethink its business strategies, with industry professionals now working together in order to explore improved pathways for drug discovery and development.

Collaboration and open innovation through Public-Private Partnerships (PPPs) enables research that would not be possible for companies to undertake individually. The consortia tackle precompetitive research – fields of activity in which large companies agree to collaborate and invest in jointly, despite their rivalry in the drug market. Most companies agree that disease biology is a precompetitive science, but that once disease targets are identified, research becomes competitive. These projects aim to eliminate duplication of research, which would waste funding and resources, and also develop competition for samples and clinical trial participation within a single patient population.

The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a huge PPP, funded by the National Institutes of Health as well as private contributions from pharmaceutical partners through the Foundations for National Institutes of Health. Alzheimer’s disease is difficult to target, as it can progress for many years before symptoms become evident. The path of disease progression is unclear, and clinical trials for any new drug have to be very lengthy, and the failure of a drug to demonstrate efficacy represents both a huge loss of investments for pharma companies, and an ongoing lack of treatment options for patients.

The initiative has produced results which have fundamentally challenged the way in which clinical trials in Alzheimer’s disease should be conducted. Previously, the length of time over which the disease can progress without symptoms was not fully appreciated, and it has become clear that anti-amyloid treatments under investigation may prove far more effective in patients with the disease at an earlier stage than those currently included in clinical trials.

The ADNI represents one of the earliest large PPPs of its type, and stakeholders worked together to decide how to manage data and intellectual property. The decision to place all data into the public domain ensured there were no intellectual property issues, and opened the newly discovered research up to the world. Though is it still uncertain how commercial companies will deal with public access to their research, increased data leveraging undoubtedly makes more sense in the eyes of a scientist or patient.

The ADNI PPP has created a sense of shared responsibility in understanding Alzheimer’s disease and has improved the landscape for clinical research in the future. This could represent a major change to the way in which pharmaceuticals are researched and value created, setting the stage for future collaborations.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Struggling Pharma Companies to Outsource Clinical Trial Research
Falling revenue in some healthcare sectors means companies are making huge efforts to reduce R&D expenditure and increase profitability.
Monday, April 23, 2012
Scientific News
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Bile Acid Supports Production of Blood Stem Cells
A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.
Chemical Used to Replace BPA is Potentially Toxic
This study is the first to examine the effects of BPA and BPS on brain cells and genes that control the growth and function of organs involved in reproduction.
A Better Model for Parkinson's
Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!